Research programme: recombinant vascular endothelial growth factor therapeutics and diagnostics - Trophogen

Drug Profile

Research programme: recombinant vascular endothelial growth factor therapeutics and diagnostics - Trophogen

Alternative Names: TROP 005

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator Trophogen
  • Class Diagnostic agents; Recombinant proteins
  • Mechanism of Action Diagnostic imaging enhancers; Vascular endothelial growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Feb 2016 Preclinical trials in Cancer (Diagnosis) in USA (unspecified route) before February 2016
  • 04 Feb 2016 Preclinical trials in Cancer in USA (unspecified route) before February 2016
  • 04 Feb 2016 Trophogen has patent protection for method of use of TROP 005 analogues in Australia, Japan and USA before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top